Zevra Therapeutics Says FDA Extends NDA Review Period For Arimoclomol
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) announced Monday the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for arimoclomol, an investigational orally delivered, first-in-class treatment for Niemann-Pick disease type C (NPC).
In addition, the FDA has set a new Prescription Drug User Fee Act (PDUFA) action date of September 21, 2024, and has re-affirmed its intent to present the resubmission for discussion at an advisory committee meeting to be scheduled.
As part of the ongoing review, Zevra received notification from the FDA that it required more time to review the additional analyses provided by the Company in responses to recent information requests generated from the FDA's review.
baca selengkapnya
Zevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type C
Rare disease therapeutics company Zevra Therapeutics, Inc. (ZVRA) announced Monday that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the New Drug Application (NDA) for arimoclomol as an orally-delivered, first-in-class treatment for Niemann-Pick disease type C.
RTTNews
|
996 hari yang lalu
Zevra Therapeutics Resubmits Arimoclomol NDA To FDA
Zevra Therapeutics, Inc. (ZVRA) announced Wednesday it resubmitted its New Drug Application (NDA) for arimoclomol to the U.S. Food and Drug Administration (FDA) on December 22, 2023. Arimoclomol is an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C (NPC).
RTTNews
|
1008 hari yang lalu
Australian Dollar Falls Following Economic Data
The Australian dollar weakened against other major currencies in the Asian session on Wednesday, despite the releases of economic data from Australia and China.
RTTNews
|
4 menit yang lalu
European Markets Seen Rising On Wednesday
A strong positive sentiment is expected to prevail in European stock markets on Wednesday amidst a sharp decline in Fed rate hike expectations. The decline in crude oil prices, the easing in bond yields and the dollar's retreat are also expected to bolster sentiment. Anxiety ahead of the release of PCE-based inflation readings from the U.S. on Wednesday morning is however expected to limit gains.
RTTNews
|
2 jam 5 menit yang lalu
Australian Dollar Falls Against Majors
The Australian dollar weakened against other major currencies in the Asian session on Wednesday.
RTTNews
|
2 jam 13 menit yang lalu
Australia Inflation Rises In August
Australia's consumer price inflation accelerated in August on higher housing and transport costs, the Australian Bureau of Statistics said Wednesday. Consumer price inflation rose to 4.0 percent from 3.5 percent in July. Inflation continues to remain above the central bank target range of 2-3 percent.
RTTNews
|
2 jam 56 menit yang lalu
China Private Sector Growth Improves
China's manufacturing and services sectors expanded at faster rates in September as robust new orders underpinned employment, survey results from S&P Global showed Wednesday. The RatingDog China general manufacturing Purchasing Managers' Index rose to 52.1 in September from 51.5 in August. The score was seen at 51.7. The index has remained above the 50.0 no-change mark.
RTTNews
|
3 jam 26 menit yang lalu
Australian Market Sharply Extends Early Gains In Mid-market
The Australian market is sharply extending its early gains in mid-market moves on Wednesday after opening in the red, adding to the gains in the previous two sessions, with the benchmark S&P/ASX 200 moving up to near the 8,800 level, despite the negative cues from Wall Street overnight, with gains in gold miners and energy stocks partially offset by weakness in iron ore miner and financial stocks.
RTTNews
|
5 jam 11 menit yang lalu
